Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1924)	10/3/2007 1:00:59 PM
From: Jibacoa	Respond to of 3722

SNSS Was up 30% after it opened with an small UG & traded up to an intraday H of 2.83 on a one minute volume of just 1,095 It is up only 11% at present.<g> bigcharts.marketwatch.com Yesterday it had closed at a new L, as it had been dropping gradually since last Thursday & past its previous Sep 7 L of 2.29 (The new L yesterday was 2.15) SNSS has 4Qs of double digit lower revenues & on the 2ndQ(June)the loss was > 2x the same Q in 2006 In May it placed 6M shares at $4.23 with some private investors.Last month it announced that it was starting a PIb of its lead product candidate, SNS-595, in combination with cytarabine for patients with relapsed and/or refractory acute leukemias. ( Previous studies showed that SNS-595 acts synergistically with cytarabine.) Its SNS-314, an Aurora kinase inhibitor, is also been started on a P1 in patients with advanced solid malignancies in an open-label trial. The drug has demonstrated anti-tumor activity in several tumor models. The insiders reportedly hold > 30% & institutions, including some Fidelity funds, >40% finance.yahoo.com The estimated losses for 2007 & 2008 are still higher than in 2006 (around $1.15 & $1.25/shr respectively vs.$1.13/shr) but with some good news, if the stock could get back to its last offering price in May, it would be a nice gain from present levels, (even if it can't get back to its IPO in Sep 2005 <g>) bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1924)	1/15/2008 12:10:47 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

VER.L Is up 10.17% with volume now 2x its ADV. bigcharts.marketwatch.com No recent news that I am aware. VER has two marketed products Apokyn to treat immobilizing episodes in patients with advanced Parkinson's disease & Frova,to treat migraine. Its V1512 is on PII also for Parkinson's, which is a disease that has been more in the limelight lately with Andy Grove & Michael J. Fox. Its V10153; V1003 & V3381 are also on PIIs for thrombotic disorders; acute pain & neuropathic pain, respectively. While its V2006 also for P.D; MMPI for inflammation & V24343 for obesity are on PIs. As previously mentioned, with some good news, VER has plent of room to run.<g> bigcharts.marketwatch.com Bernard